Nourianz Reduces Duration of ‘Off Periods’ in Parkinson’s Patients with and without Dyskinesia, Analysis Finds – Parkinson’s News Today

When used as an add-on treatment to carbidopa-levodopa, Nourianz (istradefylline) reduced the duration of “off periods” — when symptoms are not adequately controlled — and increased the duration of “on periods” in Parkinson’s disease patients with and without pre-existing dyskinesia, a pooled analysis of several clinical trials has found.

The findings, “Impact of Baseline Dyskinesia on the Safety and Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, in Patients with Parkinson’s Disease: a Pooled Analysis of 8 Clinical Studies,” were presented at the 6th Congress of the European Academy of Neurology (EAN), which took place virtually May 23–26.

Click here to read full article https://parkinsonsnewstoday.com/2020/05/29/nourianz-reduces-duration-of-off-periods-in-parkinsons-patients-with-and-without-dyskinesia-analysis-finds/

Share
Font Resize